title: Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open fractures.
abstract: The increasing incidence of bacterial infection and the appearance of Staphylococcus aureus (S. aureus) strains that are resistant to commonly used antibiotics has made it important to develop non-antibiotic approaches for infection prevention. The aim of this study was to develop local monocyte chemoattractant protein-1 (MCP-1) and interleukin-12 p70 (IL-12 p70) therapies to prevent S. aureus infection by enhancing the recruitment and activation of macrophages, which are believed to play an important role in infection prevention as the first line of defense against invading pathogens. Nanocoating systems for MCP-1 and IL-12 p70 deliveries were prepared, and their release characteristics desirable for infection prevention in open fractures were explored. Local MCP-1 therapy reduced S. aureus infection and influenced white blood cell populations, and local IL-12 p70 treatment had a more profound effect on preventing S. aureus infection. No synergistic relationship in decreasing S. aureus infection was observed when MCP-1 and IL-12 p70 treatments were combined. This reported new approach may reduce antibiotic use and antibiotic resistance.
authors: Biomaterials, Bioengineering & Nanotechnology Laboratory, Department of Orthopaedics, School of Medicine, West Virginia University, Morgantown, West Virginia 26506, USA. bli@hsc.wvu.edu
authors: Bingyun
authors: B
authors: Li
authors: Bingbing
authors: B
authors: Jiang
authors: Matthew J
authors: MJ
authors: Dietz
authors: E Suzanne
authors: ES
authors: Smith
authors: Nina B
authors: NB
authors: Clovis
authors: K Murali Krishna
authors: KM
authors: Rao
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000493:pharmacokinetics; D000818:Animals; D001864:Bone Wires / Q000009:adverse effects; D018932:Chemokine CCL2 / Q000008:administration & dosage* / Q000493:pharmacokinetics; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D005264:Femoral Fractures / Q000150:complications / Q000601:surgery; D005594:Fracture Fixation, Intramedullary / Q000009:adverse effects / Q000295:instrumentation; D005597:Fractures, Open / Q000150:complications / Q000601:surgery*; D018664:Interleukin-12 / Q000008:administration & dosage / Q000493:pharmacokinetics; D016268:Internal Fixators / Q000009:adverse effects; D008297:Male; D049329:Nanostructures; D036103:Nanotechnology / Q000379:methods; D010019:Osteomyelitis / Q000382:microbiology / Q000517:prevention & control*; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011474:Prosthesis Design; D016459:Prosthesis-Related Infections / Q000382:microbiology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects
chemical_list: D000276:Adjuvants, Immunologic; D018932:Chemokine CCL2; D020099:Coated Materials, Biocompatible; D010446:Peptide Fragments; C508645:monocyte chemoattractant protein 1 (66-77); D018664:Interleukin-12